On May 30, Goldman Sachs initiated coverage on Insulet Corporation (NASDAQ:PODD)’s stock, assigning a “Buy” rating with the price objective of $380.00, as reported by The Fly.
A pharmacy worker placing wireless handheld personal diabetes managers against the light.
The firm’s coverage is based on numerous critical factors, which are expected to fuel the company’s growth. The analysts cited the accelerating adoption of patch pump technology, where Insulet Corporation happens to be the sole player in the market. Therefore, this unique position is projected to benefit the company as the demand for such technology increases.
Furthermore, the firm hints at Insulet Corporation’s promising pipeline, which possesses the potential for closed-loop technology. This is a system that can automatically adjust insulin levels. Insulet Corporation’s pipeline provides potential to further strengthen its relative position, with sustained top-line growth likely to support outsized adjusted EBITDA results, added Goldman Sachs. Overall, the firm’s favourable outlook on Insulet Corporation stems from its innovative technology and healthy market position.
In Q1 2025, the company’s revenue came in at $569.0 million, reflecting a rise of 28.8%, or 29.8% in constant currency, as compared to $441.7 million in the prior year. The total Omnipod revenue came in at $554.1 million, implying 28.0% growth, or 29.0% in constant currency. For FY 2025, the company expects a gross margin of ~71%, up from the prior guidance of ~70.5%.
Insulet Corporation is engaged in developing, manufacturing, and selling insulin delivery systems for people with insulin-dependent diabetes.
READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now
